Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.40 (overall 0.28) | 0.40 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: eptifibatide, tirofiban, tadocizumab +3 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 16 pathways; mostly growth signalling | 0.60 |
Knock down and overexpress ITGA2B in a dopamine neuron, astrocyte and microglia tri-culture; measure phospho-ERK and phospho-AKT response to GDNF and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- phospho-ERK and phospho-AKT response to GDNF
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves phospho-ERK by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of ITGA2B in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: phospho-ERK and phospho-AKT response to GDNF; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- ITGA2B in dopamine neurons, braak-0.45 (p 0.227) → -0.42 (p 0.258)receipt 1443
Swarm cases
receipt 1443: ITGA2B in dopamine neurons, braak
- power
- full sample -0.43 (p 0.074, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.45 (p 0.063, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.036, n 18). not the mix.
- skeptic
- leave-one-out range -0.52 to -0.35, sign flips 0; without severely affected donors -0.43 (p 0.074, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGA2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts